Antineoplaston Therapy in Treating Patients With Metastatic, Recurrent, or Refractory Neuroblastoma

Stopped early · Phase 2

Conditions studied: Neuroblastoma

In brief

Current therapies for Metastatic, Recurrent, or Refractory Neuroblastoma provide very limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of Metastatic, Recurrent, or Refractory Neuroblastoma. PURPOSE: This study is being performed to determine the effects (good and bad) that Antineoplaston therapy has on patients with Metastatic, Recurrent, or Refractory Neuroblastoma.

Key facts

Study ID

NCT00003513

Run by

Burzynski Research Institute

People needed

3

Starts

1996-12-16

Expected to finish

1999-03-29

Last updated by the study team

2017-09-28

Who can join

Age: 1 and older, up to 99. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Burzynski Clinic — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.